Soma-JECT Injection
Medroxyprogesterone Acetate
150 mg/ml
Social Marketing Company
| Pack size | 1 ml |
|---|---|
| Unite Price | 38.00 BDT |
Indications
Soma-JECT Injection is used for:
Menorrhagia, endometriosis, secondary amenorrhoea, contraception, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology
Adult Dose
Oral
Amenorrhea, Uterine Bleeding
Uterine bleeding: 5-10 mg/day PO for 5-10 days; beginning day 16 or 21 of the menstrual cycle; withdrawal bleeding may be expected within 3 to 7 days after discontinuing medroxyprogesterone
Amenorrhea, secondary: 5-10 mg/day PO for 5-10 days; may be started at any time; withdrawal bleeding may be expected within 3-7 days after discontinuing medroxyprogesterone
Reduction of endometrial hyperplasia: 5 or 10 mg daily for 12 to 14 consecutive days per month, in postmenopausal women receiving daily 0.625 mg conjugated estrogens, either beginning on the 1st day of the cycle or the 16th day of the cycle.
Endometriosis: 10 mg three times a day for 90 consecutive days, beginning on the first day of the menstrual cycle
Intramuscular
Contraception
150 mg deep IM every 3 months
The initial injection should be given during the first 5 days after the onset of a normal menstrual period; within 5 days post-partum if not breast-feeding; or if exclusively breast-feeding at or after six weeks post-partum.
Child Dose
Renal Dose
Administration
May be taken with or without food. Incidence of minor indigestion may increase as dose increases. Take w/ meals if necessary.
Contra Indications
Thromboembolic disorders; cerebral apoplexy; severe hepatic dysfunction; incomplete abortion, hormone-dependent carcinoma; Undiagnosed vaginal bleeding, Undiagnosed urinary tract bleeding, Known or suspected pregnancy, Undiagnosed breast pathology, Missed abortion, Active thromboembolic disorders, Markedly impaired liver function,
Precautions
Breakthrough bleeding is likely to occur in patients being treated for endometriosis. May cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, asthma, or cardiac or renal dysfunction, require careful observation. A decrease in glucose tolerance has been observed in some patients. Patients with depression, DM, epilepsy, asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia and thromboembolic disorders.
Lactation: Safe
Pregnancy-Lactation
Pregnancy
Although therapy should not be used during pregnancy, there appears to be little or no increased risk of birth defects in women who have inadvertently been exposed to medroxyprogesterone acetate injections in early pregnancy; neonates exposed to medroxyprogesterone acetate in-utero and followed to adolescence showed no evidence of any adverse effects on their health including their physical, intellectual, sexual or social development
Lactation
Although the drug is detectable in the milk of mothers receiving therapy, milk composition, quality, and amount are not adversely affected; neonates and infants exposed to medroxyprogesterone acetate from breast milk have been studied for developmental and behavioral effects through puberty, and no adverse effects have been noted
Interactions
Aminoglutethimide and enzyme-inducing drugs (e.g. carbamazepine, griseofulvin, phenobarbital, rifampicin, phenytoin) may reduce plasma concentrations leading to reduced efficacy. Additional measures required when medroxyprogesterone is used for contraception during coadministration with these drugs.
Side Effects
Side effects of Medroxyprogesterone Acetate :
>10%
Amenorrhea, Breakthrough bleeding, Change in menstrual flow, Spotting, Edema, Anorexia, Weakness, Pain at injection site
Frequency Not Defined
Angioedema, Change in weight, Depression, Dizziness, Headache, Nervousness, Somnolence, Breast tenderness, Galactorrhea, Abdominal pain, Nausea and vomiting, Cholestatic jaundice, Deep vein thrombosis (DVT), Thrombophlebitis
Potentially Fatal: Thrombophlebitis and pulmonary embolism.
Mode of Action
Medroxyprogesterone is a synthetic progestogen which converts the proliferative phase of the endometrium into secretory phase. It has some androgenic and anabolic activities but no oestrogenic effects. Parenteral use leads to inhibition of pituitary gonadotropins, thus preventing follicular maturation and ovulation.
Note
Soma-JECT 150 mg/ml Injection generic name is Medroxyprogesterone Acetate. Soma-JECT 150 mg/ml Injection is manufactured by Social Marketing CompanySoma-JECT is availble in all over Bangladesh.
Mes BD drug index information on Soma-JECT Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.